Abstract
Chronic myeloid leukemia (CML) is a hematologic neoplasm with a progressive, ultimately terminal, disease course. In most cases, CML arises owing to the aberrant formation of a chimeric gene for a constitutively active tyrosine kinase. Inhibition of the signaling activity of this kinase has proved to be a highly successful treatment target, transforming the prognosis of patients with CML. New tyrosine kinase inhibitors continue to improve the management of CML, offering alternative options for those resistant to or intolerant of standard tyrosine kinase inhibitors. Here we review the pathobiology of CML and explore emerging strategies to optimize the management of chronic-phase CML, particularly first-line treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1433-1452 |
| Number of pages | 20 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 13 |
| Issue number | 12 |
| DOIs | |
| State | Published - Nov 29 2013 |
| Externally published | Yes |
Keywords
- Chronic myeloid leukemia
- Molecular response
- Suboptimal response
- Tyrosine kinase inhibition
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
Fingerprint Dive into the research topics of 'Tyrosine kinase inhibition: A therapeutic target for the management of chronic-phase chronic myeloid leukemia'. Together they form a unique fingerprint.
Cite this
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013). Tyrosine kinase inhibition: A therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Review of Anticancer Therapy, 13(12), 1433-1452. https://doi.org/10.1586/14737140.2013.859074